aid: metacrine name: Metacrine description: >- Metacrine, Inc. was a San Diego, California clinical-stage biopharmaceutical company founded in 2014 to develop differentiated therapies for liver and gastrointestinal disease. It built a proprietary farnesoid X receptor (FXR) platform on a distinct chemical scaffold and advanced two oral, once-daily FXR agonists — MET409 and MET642 — through Phase 1 and Phase 2 trials in non-alcoholic steatohepatitis (NASH), alongside exploratory work in inflammatory bowel disease. Backed by ARCH Venture Partners, Polaris Partners, venBio and EcoR1 Capital, it raised a $36M round in 2015 and a $65M Series C in June 2018 before pricing an initial public offering on 2020-09-15 of 6,540,000 shares at $13.00, for roughly $85.0M gross, and listing on the Nasdaq Capital Market as MTCR. Equillium, Inc. agreed to acquire the company in an all-stock transaction announced 2022-09-06, but the two mutually terminated the merger agreement on 2022-12-23. The board approved a Plan of Dissolution on 2023-01-24; Nasdaq issued a minimum-bid-price delisting notice on 2023-01-31, trading was suspended on 2023-02-09 and delisting took effect 2023-03-13; the FXR program assets were sold under a February 2023 term sheet for up to $4.0M in cash plus assumed liabilities; stockholders approved the dissolution on 2023-03-23; and the company filed a Certificate of Dissolution with the Delaware Secretary of State on 2023-03-24, effective on filing under DGCL Section 275. Metacrine was a drug developer, not a software vendor, and it never published a developer program, public API, SDK, webhook surface, or machine-readable specification of any kind. Its domain metacrine.com has since lapsed and is parked. This profile is retained as a historical record; there is no API surface to enrich. url: https://raw.githubusercontent.com/api-evangelist/metacrine/refs/heads/main/apis.yml x-api-posture: no-product-api x-api-posture-basis: observed x-api-posture-note: "Metacrine was a drug developer, not a software vendor, and it never published a developer program, public API, SDK, webhook surface, or machine-readable specification of any kind." x-type: company x-source: harvest:secondary-market x-tier: stub x-tier-reason: defunct-no-api-surface x-status: defunct x-founded: '2014' x-headquarters: San Diego, California, United States x-ticker: 'NASDAQ: MTCR (delisted 2023-03-13)' x-shutdown-date: '2023-03-24' x-shutdown-note: >- Stockholders approved a Plan of Dissolution on 2023-03-23 and the company filed a Certificate of Dissolution with the Delaware Secretary of State on 2023-03-24, effective upon filing under DGCL Section 275. Under DGCL Section 278 the corporate existence continues at least three years solely to wind up affairs. Confirmed from the company's own Form 8-K (SEC CIK 0001634379). x-domain-status: expired-parked x-domain-note: >- metacrine.com was registered 2014-11-11 through Network Solutions — the company's own original registration — but has lapsed and is now delegated to NS1/NS2.PENDINGRENEWALDELETION.COM and wildcarded to the Media.net/Confluence Networks parking address 208.91.197.132. Every subdomain (www, api, docs, developer, developers, app, investors) resolves to that same address, TLS on 443 resets before a handshake, and every path returns HTTP 200 with a 122- or 195-byte "Error. Page cannot be displayed" stub — including a control path that cannot exist. Those 200s are not documents. See well-known/metacrine-well-known.yml. metacrine.com is NOT wired as a Website pointer. deliveryModel: model: unknown open_source: false commercial: false callable_host: false label: Delivery model not determined — needs a product licence on record confidence: low source: - none generated: '2026-08-28' method: derived specificationVersion: '0.23' created: '2026-08-25' modified: '2026-08-25' tags: - Company - Defunct - Biotechnology - Pharmaceuticals - Life Sciences - Clinical Trials - Drug Discovery - Therapeutics - Healthcare apis: [] maintainers: - FN: Kin Lane email: kin@apievangelist.com - FN: APIs.json email: info@apis.io common: - type: SecondaryMarket url: https://forgeglobal.com/metacrine_stock/ - type: WellKnownProbe url: well-known/metacrine-well-known.yml x-coverage: state: none reason: defunct detail: >- Metacrine, Inc. was a clinical-stage biopharmaceutical developer that never shipped software, and it filed a Certificate of Dissolution with the Delaware Secretary of State on 2023-03-24; its original domain metacrine.com has since lapsed onto Network Solutions' PENDINGRENEWALDELETION nameservers and a Media.net parking wildcard that answers HTTP 200 with the same 122-byte "Error. Page cannot be displayed" stub for every path and every subdomain, including a control path that cannot exist, so none of those 200s is a document. evidence: - url: https://www.sec.gov/Archives/edgar/data/1634379/000119312523079293/d453945d8k.htm status: 200 - url: http://metacrine.com/ status: 200 - url: http://metacrine.com/openapi.json status: 200 - url: http://metacrine.com/.well-known/agent-card.json status: 200 - url: http://metacrine.com/control-path-does-not-exist-98765 status: 200 - url: https://metacrine.com/ status: 0 - url: https://api.github.com/orgs/metacrine status: 404 - url: https://registry.npmjs.org/metacrine status: 404 - url: https://forgeglobal.com/metacrine_stock/ status: 403 checked: '2026-08-25' x-enrichment: date: '2026-08-25' status: minimal artifacts_added: 1 pass: local-v1